Lifecore Sets 2026 Annual Meeting, Proposal Deadlines

An update from Lifecore Biomedical ( (LFCR) ) is now available.

On August 1, 2025, Lifecore Biomedical’s board approved a shift in its fiscal year from one ending on the last Sunday in May to a calendar-year basis ending December 31, effective for the fiscal period from May 26, 2025 to December 31, 2025, aligning its SEC reporting and annual meeting schedule with calendar-year reporting norms. Reflecting this change, on March 5, 2026 the board set June 4, 2026 as the date of the 2026 annual shareholders’ meeting, and moved the deadline for qualified shareholder proposals and director nominations to March 16, 2026, with submissions required to meet SEC rules, the company’s bylaws, and Delaware law.

The most recent analyst rating on (LFCR) stock is a Sell with a $6.50 price target. To see the full list of analyst forecasts on Lifecore Biomedical stock, see the LFCR Stock Forecast page.

Spark’s Take on LFCR Stock

According to Spark, TipRanks’ AI Analyst, LFCR is a Neutral.

The score is primarily held down by weak financial performance (ongoing losses, high leverage, and challenged cash flow). Technicals provide some support with the stock trading above key moving averages and neutral momentum, while valuation remains constrained by negative earnings (negative P/E). A recent incentive-plan change is a minor positive but not a fundamental offset to the financial risks.

To see Spark’s full report on LFCR stock, click here.

More about Lifecore Biomedical

Lifecore Biomedical, Inc. operates in the biomedical and life sciences industry, focusing on specialized health-care products and services. The company is publicly listed and subject to U.S. securities regulations, with governance practices centered on shareholder meetings and SEC-compliant disclosure and reporting.

Average Trading Volume: 142,801

Technical Sentiment Signal: Sell

Current Market Cap: $261.9M

For an in-depth examination of LFCR stock, go to TipRanks’ Overview page.